Tango Therapeutics reports 82% response rate for vopimetostat combination in pancreatic cancer trial

Bitget2026/10/23 10:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tango Therapeutics reported tumor shrinkage and durable disease control with vopimetostat combined with daraxonrasib in previously treated pancreatic cancer.
The Phase 1/2 results are being presented at the ESMO Congress in Madrid, Oct. 23-27, 2026.
The lower-dose combination was generally well tolerated; the higher-dose regimen was not well tolerated.
A registrational Phase 3 trial comparing the combination against chemotherapy in previously untreated, MTAP-deleted pancreatic cancer is planned for first-half 2027.
Discussions with regulators will explore potential approval of the combination for second-line pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230630PRIMZONEFULLFEED9851825) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tango Therapeutics reports 82% response rate for vopimetostat combination in pancreatic cancer trial

You may also like

Crypto prices